SSKN — STRATA Skin Sciences, Inc.

Summary of STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $6.9 million, down 20% year-over-year, primarily due to challenges in international markets.
• Recurring Revenue:
  • Gross code sales increased by 4.1%.
  • Net U.S. recurring XTRAC revenue rose by 2.8%.
  • Global recurring revenue totaled $5.5 million, up 3% year-over-year.
• Equipment Revenue: $1.4 million, a significant decrease of 60% compared to the prior year.
• Gross Profit: $4.2 million (60% of revenue), with gross margin stable year-over-year.
• Operating Expenses: Reduced to $5.4 million from $6.9 million in the previous year, largely due to a one-time sales tax accrual in 2024.
• Net Loss: $1.6 million, or EPS of -$0.36, an improvement from a net loss of $2.1 million (EPS of -$0.51) in 2024.
• Adjusted EBITDA: Slightly positive, compared to a negative $240,000 in the same quarter last year.
• Cash Position: $7.1 million as of September 30, 2025.

2. Strategic Updates and Business Highlights

• CPT Code Expansion: Anticipated expansion of CPT codes for XTRAC laser treatments effective January 1, 2027, which will broaden reimbursement eligibility to over 30 million patients and increase revenue potential significantly.
• Elevate360 Program: 99 out of 838 partner clinics have adopted this program, resulting in an average growth of 7% year-over-year for participating clinics. Average gross billings per device increased to $5,981, the highest since 2022.
• International Expansion: Initial commercial placements of TheraClear technology in Mexico have been achieved, with plans for further expansion.
• Litigation Update: STRATA is pursuing a case against LaserOptik for misleading marketing, which could result in significant damages and the return of lost accounts.

3. Forward Guidance and Outlook

• The company expects a seasonally stronger fourth quarter in 2025 and anticipates significant revenue growth from expanded indications for XTRAC treatments.
• STRATA aims to increase its installed base of devices and improve utilization through ongoing strategic initiatives.

4. Bad News, Challenges, or Points of Concern

• International Revenue Challenges: Ongoing difficulties in international markets, attributed to U.S. trade policies, have pressured total revenue.
• Equipment Revenue Decline: A sharp decrease in equipment revenue raises concerns about future capital sales.
• Litigation Risks: While the ongoing litigation presents potential upside, it also carries risks and uncertainties that could impact business operations.
• Tariffs Impact: The lingering effects of tariffs on international business may continue to pose challenges.

5. Notable Q&A Insights

• Average Revenue per Device: Increased to $5,981, with a focus on removing non-productive devices to enhance overall revenue.
• DTC Campaign Effectiveness: The company reported improved show-up rates and patient conversion due to targeted DTC strategies, although specific patient numbers were not disclosed.
• Future Device Installations: STRATA aims to increase its U.S. installed base of TheraClear devices to approximately 200 by the end of 2025.
• Temporary CPT Codes: The possibility of temporary codes for 2026 was ruled out by CMS, focusing instead on the established codes for 2027.

Overall, while STRATA Skin Sciences faces challenges, particularly in international markets and equipment sales, the company is strategically positioned for growth with upcoming CPT code expansions and successful initiatives like Elevate360.